Novelion's Aegerion resolves U.S. drug probes for $40 million

BOSTON (Reuters) - Aegerion Pharmaceuticals Inc will plead guilty to two misdemeanors and pay $40 million to resolve investigations into its marketing and sales of a cholesterol drug, U.S. prosecutors and regulators announced on Friday.